Skip to main content
OpenTrials

Clinical trial condition

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Explore clinical trials studying Metastatic Hormone-Sensitive Prostate Cancer (mHSPC). Study availability and eligibility vary by location and protocol.

22 public trials 10 recruiting studies
Refine in advanced search Browse all conditions

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) trial results

Recruiting

Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer

NCT07140900

Conditions
Genital Diseases, Genital Diseases, Male, Genital Neoplasms, Male, +8 more
Locations
  • University of California San Francisco San Francisco, California, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • University of Minnesota Minneapolis, Minnesota, United States
  • Cleveland Clinic Foundation Cleveland, Ohio, United States
View all 16 locations
View Trial Details
Recruiting

TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

NCT07190300

Conditions
Bulbo-Spinal Atrophy, X-Linked, Central Nervous System Diseases, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, +10 more
Locations
  • Univ of Alabama at Birmingham Birmingham, Alabama, United States
  • Uni Of Iowa Hospitals And Clinics Iowa City, Iowa, United States
  • University of Kansas Cancer Center Westwood, Kansas, United States
  • Wichita Urology Group PA Wichita, Kansas, United States
View all 31 locations
View Trial Details

Related conditions